Revolution Medicines
Senior Director, Global Value Access and Pricing, NSCLC
Redwood City, California, United States · Director · Full-time
Sponsorship not specified$244k-$305kDetected 22 hours ago
ComplianceProduct ManagementStakeholder ManagementBusiness DevelopmentLeadershipCommunicationMentoring
About the role
- The Senior Director, Global Value, Access & Pricing NSCLC Oncology is accountable for defining and driving global value, access, and pricing strategies for Revolution Medicines' oncology assets.
- This role serves as the strategic market access leader across the asset lifecycle, ensuring payer, HTA, pricing, reimbursement, and evidence-generation considerations are integrated into development, launch, and commercialization decisions.
Responsibilities
- Define and drive the global value, access, and pricing strategy for oncology assets across the product lifecycle, ensuring alignment with portfolio objectives, long-term asset value, and sustainable patient access.
- Develop differentiated global value propositions and pricing strategies, including launch sequencing, pricing architecture, reference pricing considerations, and net price corridor management across major markets.
- Lead global market access and HTA readiness, including EU Joint Clinical Assessment (JCA) strategy, in partnership with European teams to align evidence generation, value strategy, and access objectives.
- Partner across global and regional functions to ensure market access considerations are integrated into development, launch, commercialization, and lifecycle planning.
- Demonstrated success influencing clinical development, evidence generation, launch planning, and commercialization strategies to optimize payer and HTA outcomes.
Requirements
- 12+ years of progressive experience in market access, pricing, HEOR, commercial strategy, or related functions within the biopharmaceutical industry, including global leadership responsibilities.
- Strong strategic, analytical, and decision-making capabilities, with the ability to translate complex business challenges into actionable recommendations.
Nice to have
- advanced degree (PhD, PharmD, MD, MBA, MPH, MSc, or equivalent) preferred.
- Bachelor's degree required
Skills
- Bachelor's degree required; advanced degree (PhD, PharmD, MD, MBA, MPH, MSc, or equivalent) preferred.
- Experience in thoracic oncology, lung cancer, precision oncology, or biomarker-driven therapies.
- Understanding of companion diagnostic reimbursement and testing access considerations.
- Familiarity with emerging global healthcare policy and pricing reforms, including U.S. IRA, EU pharmaceutical legislation, and EU JCA.
- Experience in a clinical-stage, pre-commercial, or rapidly growing biotechnology environment.
- #LI-JW1 #LI-Remote
- The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below.
- For additional information, please contact privacy@revmed.com.
- Base Pay Salary Range
- $244,000 - $305,000 USD
- All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
Compensation
- $244,000 - $305,000 USD
- Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process.
Benefits
- Serve as a strategic advisor to senior leadership on pricing, reimbursement, launch readiness, lifecycle management, portfolio prioritization, and business development opportunities.
- Required Skills, Experience and Education:
- Deep expertise in global pricing, reimbursement, market access, and oncology product development, with a strong understanding of payer systems, HTA processes, and evolving reimbursement frameworks across major markets.
Company info
- Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
- The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
- The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
- As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.
Apply directly at Revolution Medicines →Create a free account for alerts like thisView Revolution Medicines immigration profile
This listing is sourced directly from Revolution Medicines's careers page and normalized into a canonical job model.